Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SII-TCV (B)
- Development stage
- Phase 2
- Lead developer
- Serum Institute of India
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**SII-TCV (B)** is an investigational bivalent glycoconjugate vaccine developed and manufactured by Serum Institute of India for prevention of enteric fever caused by *Salmonella enterica* serovar Typhi and *Salmonella enterica* serovar Paratyphi A. It contains *S. Typhi* Vi capsular polysaccharide conjugated to tetanus toxoid and *S. Paratyphi* A O-specific polysaccharide O:2 conjugated to diphtheria toxoid. Intramuscular vaccination is intended to induce antigen-specific anti-Vi and anti-O:2 humoral immunity, including functional bactericidal antibodies against *S. Paratyphi* A. A completed Phase I trial in healthy Indian adults found the vaccine to be safe and immunogenic; it is being evaluated in the Phase II BiVISTA controlled human infection model study in healthy UK adults. ([ora.ox.ac.uk](https://ora.ox.ac.uk/objects/uuid%3A30d77f79-da10-4995-a45a-a0a4beb02e54/files/rj38608007))
- Other names
- bivalent paratyphoid A-typhoid conjugate vaccineSerum Institute of India Typhoid Conjugate Vaccine Bivalent
02
Targets
Paratyphi A antigen (Salmonella Paratyphi A antigen)Vi antigen (Vi capsular polysaccharide)O:2 lipopolysaccharide of Salmonella enterica serovar Paratyphi A
Beyond the preview
Go deeper on SII-TCV (B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SII-TCV (B).